SWK — Investor Presentation (April 2023)
33 slides from SWK's investor presentation, Apr 4, 2023
Slide 1: Collaborative Approach to Life Science Financing Shareholder Presentation
1 Collaborative Approach to Life Science Financing Shareholder Presentation April 3, 2023
Slide 2: Forward-looking and Cautionary Statements
2 Forward - looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we be lieve or anticipate will or may occur in the future are "forward - looking" statements within the meaning of the federal secu
Slide 3: SWK Holdings - Overview
SWK Holdings - Overview 3 Underserved, High - Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial - stage healthcare companies and royalty owners • SWK targets $5mm to $25mm financings, a market niche that is largely ignored by
Slide 4: SWK Holdings - Segments
4 SWK Holdings - Segments LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Royalties • Synthetic royalties • Hybrid structures • Peptelligence ® and ProPerma Œ dosing technologies • CDMO and CMO services • 505b2 drug development SWK operates through two segments: Life S
Slide 5: Life Science Finance Opportunity
5 Life Science Finance Opportunity Achieve high current yield from investment in non - correlated assets Access to capital is challenging for small/mid - sized life science companies - Few participants exist for sub - $25mm life science financings Life science products are highly portable - Approved
Slide 6: Value Creation Strategy
6 Value Creation Strategy Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go - to capital provider for this underserved market • Majority of financings structured with warrants or other equity - like upside features to enhance return profile Optimi
Slide 7: Book Value Components
7 Book Value Components Tangible Finance Book Value / Share = $19.02 • Excludes value of deferred tax asset, net Enteris intangibles and goodwill * , and Enteris PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: Enteris Biopharma Net Book Value / Share = $0.87 • In 2019, SW
Slide 8: Corporate Milestones
8 Corporate Milestones 2016 x Team rebuilt and investment process improved x Ended year with $130.0mm investment assets 2017 x Holmdel sold – 3.5x CoC return x Ended year with $154.9mm investment assets 2018 x Secured $20mm credit facility with Cadence Bank (f/k/a State Bank) x Announced share repur
Slide 9: Fourth Quarter 2022 Recap
Fourth Quarter 2022 Recap 9 CONFIDENTIAL CORPORATE UPDATES FINANCE RECEIVABLES UPDATES • Jody Staggs named President and Chief Executive Officer • Yvette Heinrichson named Chief Financial Officer • Dr. Paul Shields named Chief Executive Officer of Enteris • During the fourth quarter of 2022, closed
Slide 10: Finance Segment Portfolio Overview: 4Q22
10 Finance Segment Portfolio Overview: 4Q22 * Finance receivables and marketable investments; does not include new or repaid finance receivables closed post - quarter. ** Includes public company warrants; private warrants carried at zero value / not valued on balance sheet • Yielding Assets: * $236.
Slide 11: Financial Snapshot
11 Financial Snapshot * Eliminates provision for income taxes, Enteris intangibles amortization, and non - cash mark - to - market changes on warrant assets and equity securities; see reconciliation on page 30; 2019 Non - GAAP Adjusted Net Income was reduced by $1.2mm of Enteris transaction expenses
Slide 12: Financing Strategy: Effective Yields
12 Financing Strategy SWK Targets Low - to - Mid Teens Effective Yields 4Q22 Finance Segment Effective Yield was 13.9% * Effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recognition poli cie s, if all payments are received pursuant to the ter
Slide 13: Financing Strategy: Realized Yield vs Projected
13 Financing Strategy SWK’s Portfolio Realized Yield Has Consistently Exceeded the Projected Yield as Actual Receipts Exceeded Internal Forecasts *Portfolio Realized Yield is inclusive of all fees and is calculated based on the simple average of finance receivables at th e b eginning and end of peri
Slide 14: Current Structured Credit Portfolio
14 Current Structured Credit Portfolio Trio Healthcare 07.01.2021 $9.5 million Structured Credit Advanced Oxygen Therapy 03.21.2022 $12.0 million Structured Credit Aziyo Biologics 08.10.2022 $25.0 million Structured Credit BIOLASE 11.09.2018 $15.0 million Structured Credit Biotricity 12.27.2021 $12.
Slide 15: Current Royalty Portfolio
15 Current Royalty Portfolio Best ABT 11.12.2018 $5.8 million Royalty Reorganization Cambia 07.31.2014 $9.5 million Royalty Acquisition ForFivo ( IntelGenx ) 08.05.2016 $6.0 million Royalty Acquisition Illuvien 12.18.2020 $16.5 million Royalty Acquisition Women’s Health 06.07.2013 $3.0 million Royal
Slide 16: Portfolio Realizations
16 Portfolio Realizations $ in 000s # Investments Security Origination Payoff Cash Invested Cash Received MOIC XIRR Exit Form Factor 1 Nautilus Loan 12/05/12 12/17/13 22,500$ 28,606$ 1.3x 28%Acquired by Strategic 2 Parnell I Loan 01/23/14 06/27/14 25,000$ 27,110$ 1.1x 21% Refinanced 3 Response Genet
Slide 17: Portfolio Realizations to Strategic Buyers
17 Portfolio Realizations to Strategic Buyers 13 realizations to strategic buyers demonstrated a median 28% LTV of SWK’s original loan value 9 of the 13 businesses were not profitable at time of sale, validating SWK’s revenue and IP - based underwriting methodology $ in mm Target Buyer Closing Date
Slide 18: Sourcing
18 Sourcing • SWK has a well - developed and diversified sourcing network • SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers • SWK typically faces limited competition due to proprietary sourcing network and focus on sub - $25mm financings • Fr
Slide 19: Financing Structures
Financing Structures 19 Product Acquisition • Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commer
Slide 20: Value Proposition to Partners
20 Value Proposition to Partners Smaller companies often don’t have financial profile to qualify for traditional financing sources Companies in this niche often have few options outside of a dilutive equity raise The IPO market is largely closed to companies of this size requiring expensive and diff
Slide 21: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty 21 OPPORTUNITY SOLUTION • Opiant is a publicly - traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation • Novel formulation has a faster time to onset and more convenient and safer administration • Opiant ne
Slide 22: Historical Financing: Galil Medical
Historical Financing: Galil Medical 22 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cash - flow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In
Slide 23: Enteris Corporate Overview
23 Enteris Corporate Overview CDMO Platform Proven Technology, Late - Stage Commercial Partnerships, and Internal Pipeline Drug Delivery Technology Internal 505(b)(2) Pipeline Company Highlights • Peptelligence and ProPerma allow for oral delivery of drugs that are typically injected, including pept
Slide 24: Enteris: Cara Therapeutics and Oral KORSUVA
Enteris: Cara Therapeutics and Oral KORSUVA Œ 24 Oral KORSUVA Licensing Agreement Milestone Payment • Formulated with Enteris ’ Peptelligence technology • Currently the subject of three late - stage clinical trials for pruritus: • Phase 3 trial targeting pruritus associated with non - dialysis depen
Slide 25: Leadership Team
25 Leadership Team Yvette Heinrichson Chief Financial Officer • Joined in 2016 • Technical GAAP accounting and SEC financial reporting • Certified Fraud Examiner • Served as financial statement auditor and tax professional with Deloitte for multiple years Jody Staggs President and Interim CEO • Join
Slide 26: Why Invest in SWKH - Attractive Risk Reward Scenario
Why Invest in SWKH – Attractive Risk Reward Scenario 26 Unleveraged Balance Sheet and Buyback • SWK story is not widely known, having uplisted to Nasdaq without benefit of traditional IPO • Analyst coverage and proactive investor relations effort have helped to increase SWK’s visibility • With a Boo
Slide 27: Balance Sheet
27 Balance Sheet Certain asset and liabilities were classified as “current” in prior years; thus, prior periods may not be directly comparable . $ in 000s Dec-22 Dec-21 Dec-20 Dec-19 Dec-18 ASSETS Cash and cash equivalents 6,156$ 42,863$ 3,008$ 11,158$ 20,227$ Interest and accounts receivable,net 3,
Slide 28: Income Statement
28 Income Statement $ in 000s, except per share amounts Dec-22 Dec-21 Dec-20 Dec-19 Dec-18 Revenues Finance receivable interest income, including fees 35,461$ 39,310$ 30,800$ 30,117$ 25,978$ Pharmaceutical development 5,485 16,122 5,903 621 - Other 538 723 9 9 12 Total revenues 41,484 56,155 36,712
Slide 29: Cash Flow Statement
29 Cash Flow Statement $ in 000s Dec-22 Dec-21 Dec-20 Dec-19 Dec-18 Cash flows from operating activities Net income 13,491$ 25,929$ 5,202$ 23,828$ 6,195$ Adjustments to reconcile net income to net cash provided by operating activities Provision for loan credit losses 3,491 - - 2,209 6,179 Impairment
Slide 30: Reconciliation of Non-GAAP Adjusted Net Income
30 Reconciliation of Non - GAAP Adjusted Net Income The following tables provide a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated ne t income (Non - GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non - cas
Slide 31: Reconciliation of Non-GAAP Specialty Finance Net Income
31 Reconciliation of Non - GAAP Specialty Finance Net Income The following tables provide a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non - GAAP adjusted net income for the specialty finance business for the periods deno
Slide 32: Contact Information
32 Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Tiberend Strategic Advisor • Jody Staggs: ̶ Phone: 972.687.7252 ̶ Email: jstaggs@swkhold.com • Office address: ̶ 14755 Preston Road, Ste 105 Dallas, TX 75254 • Website: www.swkhold.com • Jason Rando: ̶ Email: jrand
Slide 33: Collaborative Approach to Life Science Financing
33 Collaborative Approach to Life Science Financing